Correlation Between Iovance Biotherapeutics and DBV Technologies

Can any of the company-specific risk be diversified away by investing in both Iovance Biotherapeutics and DBV Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iovance Biotherapeutics and DBV Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Iovance Biotherapeutics and DBV Technologies, you can compare the effects of market volatilities on Iovance Biotherapeutics and DBV Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iovance Biotherapeutics with a short position of DBV Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iovance Biotherapeutics and DBV Technologies.

Diversification Opportunities for Iovance Biotherapeutics and DBV Technologies

0.51

Correlation Coefficient

Iovance Biotherapeutics  DBV Technologies

Very weak diversification

The 3 months correlation between Iovance and DBV is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Iovance Biotherapeutics and DBV Technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DBV Technologies and Iovance Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iovance Biotherapeutics are associated (or correlated) with DBV Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DBV Technologies has no effect on the direction of Iovance Biotherapeutics i.e., Iovance Biotherapeutics and DBV Technologies go up and down completely randomly.

Pair Corralation between Iovance Biotherapeutics and DBV Technologies

Given the investment horizon of 90 days Iovance Biotherapeutics is expected to under-perform the DBV Technologies. But the stock apears to be less risky and, when comparing its historical volatility, Iovance Biotherapeutics is 2.65 times less risky than DBV Technologies. The stock trades about -0.1 of its potential returns per unit of risk. The DBV Technologies is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  280.00  in DBV Technologies on September 15, 2024 and sell it today you would earn a total of  77.00  from holding DBV Technologies or generate 27.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Iovance Biotherapeutics  vs.  DBV Technologies

Iovance Biotherapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

DBV Technologies

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in DBV Technologies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, DBV Technologies may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Iovance Biotherapeutics and DBV Technologies

The main advantage of trading using opposite Iovance Biotherapeutics and DBV Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iovance Biotherapeutics position performs unexpectedly, DBV Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will offset losses from the drop in DBV Technologies' long position.

The idea behind Iovance Biotherapeutics and DBV Technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .